Publikationen | Märkische Kliniken
Zu den Inhalten springen

Klinik für Neurologie

Publikationen

2015

  • Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang, R, Viglietta V, Dawson KT; CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015 Mar 17;84(11):1145-52
  • Hoffmann F, Kraft A, Heigl F, Mauch E, Koehler J, Harms L, Kümpfel T, KöhlerW, Klingel R, Fassbender C, Schimrigk S. [Tryptophan immunoadsorption for multiple sclerosis and neuromyelitis optica: therapy option for acute relapses during pregnancy and breastfeeding]. Nervenarzt. 2015 Feb;86(2):179-86. 

2014 - 2011

  • Büssing A, Wirth AG, Reiser F, Zahn A, Humbroich K, Gerbershagen K, Schimrigk S, Haupts M, Hvidt NC, Baumann K. Experience of gratitude, awe and beauty in life among patients with multiple sclerosis and psychiatric disorders. Health Qual Life Outcomes. 2014 Apr 30;12:63. doi: 10.1186/1477-7525-12-63. 
  • Büssing A, Wirth AG, Humbroich K, Gerbershagen K, Schimrigk S, Haupts M, Baumann K, Heusser P. Faith as a resource in patients with multiple sclerosis is  associated with a positive interpretation of illness and experience of gratitude/awe. Evid Based Complement Alternat Med. 2013;2013:128575. doi: 10.1155/2013/128575. Epub 2013 Nov 10. PubMed PMID: 24319471; PubMed Central
  • Wolinsky JS, Narayana PA, Nelson F, Datta S, O'Connor P, Confavreux C, Comi G, Kappos L, Olsson TP, Truffinet P, Wang L, Miller A, Freedman MS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes  from a phase III trial of teriflunomide. Mult Scler. 2013 Sep;19(10):1310-9. doi: 10.1177/1352458513475723. Epub 2013 Feb 27. PubMed PMID: 23447359.
  • Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1087-97. Erratum in: N Engl J Med. 2012 Oct 25;367(17):1673. PubMed PMID: 22992072.
  • Humbroich K, Schimrigk S. [CLIPPERS: an increasingly diagnosed syndrome]. Nervenarzt. 2012 Jun;83(6):782-4. doi: 10.1007/s00115-012-3481-1. German. PubMed  PMID: 22476512.
  • Patsopoulos NA; Bayer Pharma MS Genetics Working Group; Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist; ANZgene Consortium; GeneMSA; International Multiple Sclerosis Genetics Consortium, Esposito F, Reischl J, Lehr S, Bauer D, Heubach J, Sandbrink R, Pohl C,  Edan G, Kappos L, Miller D, Montalbán J, Polman CH, Freedman MS, Hartung HP, Arnason BG, Comi G, Cook S, Filippi M,  Goodin DS, Jeffery D, O'Connor P, Ebers GC, Langdon D, Reder AT, Traboulsee A,  Zipp F, Schimrigk S, Hillert J, Bahlo M, Booth DR, Broadley S, Brown MA, Browning BL, Browning SR, Butzkueven H, Carroll WM, Chapman C, Foote SJ, Griffiths L, Kermode AG, Kilpatrick TJ, Lechner-Scott J, Marriott M, Mason D, Moscato P, Heard RN, Pender MP, Perreau VM, Perera D, Rubio JP, Scott RJ, Slee M, Stankovich J, Stewart GJ, Taylor BV, Tubridy N, Willoughby E, Wiley J, Matthews P, Boneschi FM, Compston A, Haines J, Hauser SL, McCauley J, Ivinson A, Oksenberg JR, Peri ak-Vance M, Sawcer SJ, De Jager PL, Hafler DA, de Bakker PI. Genome-wide Met a-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011 Dec;70(6):897-912. doi: 10.1002/ana.22609. Erratum in: Ann Neurol. 2013 Apr;73(4):561. PubMed PMID: 22190364; PubMed Central PMCID: PMC3247076.
  • O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011  Oct 6;365(14):1293-303. doi: 10.1056/NEJMoa1014656. PubMed PMID: 21991951.
  • Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, Ferenczi L, Verco T; MAESTRO-01 Investigators. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.  Neurology. 2011 Oct 18;77(16):1551-60. doi: 10.1212/WNL.0b013e318233b240. Epub 2011 Oct 5. PubMed PMID: 21975206.
  • Hellwig K, Schimrigk S, Chan A, Epplen J, Gold R. A newborn with Pierre Robin  sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. J Neurol Sci. 2011 Aug 15;307(1-2):164-5. doi: 10.1016/j.jns.2011.05.003. Epub 2011 May 20. PubMed PMID: 21601225.

2009

  • Bellenberg B, Schimrigk S,  Brück K, Tönnes C, Chan A, Klein J, Hahn H K,  Köster O,  Lukas C. Third ventricle enlargement correlates to different patterns of regional fiber integrity in the Corpus Callosum of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis Patients 2009
  • Khil L, Flachenecker P, Zettl UK, Elias W, Freidel M, Haas J, Pitschnau-Michel D, Schimrigk S, Rieckmann P. Update on the German MS Register. Immunotherapy and drug discontinuation
    German Multiple Sclerosis Society, National Association, Hannover, Germany 2009
  • Grey and white matter atrophy in MS: associations to corticospinal tract degeneration and upper spinal cord atrophy are restricted to relapsing-remitting MS
    Barbara Bellenberg1, Sebastian Schimrigk1, Kerstin Brück3, Jan Klein2, Horst K Hahn2, Odo Köster3, Carsten Lukas3
    Vortrag und Posterpräsentation European Congress of Radiology, Wien 2009
  • Patientenversorgung bei Multipler Sklerose: Vergleich der Basisdaten verschiedener Versorgungsstrukturen im Deutschen MS-Register
    L. Khil, P. Flachenecker, U. K. Zettl, W. Elias, M. Freidel, J. Haas, D. Pitschnau-Michel, S. Schimrigk, P. Rieckmann
    Vortrag und Posterpräsentation DGN 2009, Mannheim
  • Update on the German MS Register: Immunotherapy and drug discontinuation
    Khil L, Flachenecker P, Zettl UK, Elias W, Freidel M, Haas J, Pitschnau-Michel D, Schimrigk S, Rieckmann P and the German Multiple Sclerosis Society, National Association, Hannover, Germany
    Posterpräsentation ENS 2009
  • Multiple Sklerose und die interhemisphärische Integration. Eine kombinierte Struktur-Funktions-Analyse
    Barbara Bellenberg, Carsten Lukas, Axel Eberl, Christian Beste, Markus Hausmann, Odo Köster, Sebastian Schimrigk
    Posterpräsentation und Vortrag. Forschungsförderung FoRum 12/2009
  • De Jager PL, Chibnik LB, Cui J, Reischl J, Lehr S, Simon KC, Aubin C, Bauer D, Heubach JF, Sandbrink R, Tyblova M, Lelkova P; Steering committee of the BENEFIT study; Steering committee of the BEYOND study; Steering committee of the LTFstudy; Steering committee of the CCR1 study, Havrdova E, Pohl C, Horakova D,Ascherio A, Hafler DA, Karlson EW. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol. 2009 Dec;8(12):1111-9. Epub 2009 Oct 29. 
  • Stuke K, Flachenecker P, Zettl UK, Elias WG, Freidel M, Haas J, Pitschnau-Michel D, Schimrigk S, Rieckmann P. Symptomatology of MS: results from the German MS Registry. J Neurol. 2009 Nov;256(11):1932-5. Epub 2009 Jul 23.
  • Hellwig K, Schimrigk S, Beste C, Muller T, Gold R. Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. EurNeurol. 2009;61(2):65-8. 
  • Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN; BG-12 Phase IIb Study Investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008 Oct 25;372(9648):1463-72. Erratum in: Lancet. 2009 Apr 18;373(9672):1340.

2008

  • Hellwig K, Schimrigk S, Beste C, Muller T, Gold R. Increase in Relapse Rate during Assisted Reproduction Technique in Patients with Multiple Sclerosis. Eur Neurol. 2008 Nov 28;61(2):65-68. 
  • Hellwig K, Schimrigk S, Fischer M, Haghikia A, Müller T, Chan A and Gold R. Allergic and non-allergic delayed infusion reactions during natalizumab therapy. Archives of Neurology in press 9-07 
  • Haupts, M.R., Schimrigk, S., Brune, N., Chan, A., Ahle, G., Hellwig, K., König, F.B., Schlegel, U., Brück, W., Gold, R., Fulminant tumefactive multiple sclerosis: Therapeutic implications of histopathology. Journal of Neurology. (in press) 
  • Hellwig K, Schimrigk S, Fischer M, Haghikia A, Müller T, Chan A, Gold R., Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol. 2008 May;65(5):656-8. 
  • Lukas C, Hahn HK, Bellenberg B, Hellwig K, Globas C, Schimrigk S, Köster O, Schöls L., Spinal cord atrophy in spinocerebellar ataxia type 3 and 6 : Impact on clinical disability. J Neurol. 2008 Jun 5. 
  • Hellwig K, Beste C, Brune N, Haghikia A, Müller T, Schimrigk S, Gold R., Increased MS relapse rate during assisted reproduction technique. J Neurol. 2008  Apr;255(4):592-3. 
  • Hellwig K, Brune N, Haghikia A, Müller T, Schimrigk S, Schwödiauer V, Gold R., Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand. 2008 Jan 16.

2007

  • Schimrigk S, Bellenberg B, Brune N, Drescher , Lukas C, Pöhlau D, Przuntek H, Köster O DTI based fractional anisotropy quantification in the corticospinal tract of ALS patients using a probabilistic mixture model. AmJ NeuroRad 2007 
  • Kerstin Hellwig MD, Sebastian Schimrigk MD, Malte Fischer MD, Aiden Haghikia MD, Thomas Müller MD, Andrew Chan MD and Ralf Gold MD. Allergic and non-allergic delayed infusion reactions during natalizumab therapy. Eingereicht bei annals of neurology 9/2007 
  • Kerstin Hellwig MD1, Sebastian Schimrigk MD2, Christian Beste PhD1, Ralf Gold MD. Multiple sclerosis relapse rate is not increasing during assisted reproduction technique. 10/2007 eingereicht bei archives of neurology 
  • P. Flachenecker, U. K. Zettl, U. Götze, K. Stuke, W. Elias, M. Eulitz, J. Haas, M. Pette, D. Pitschnau-Michel, S. Schimrigk, P. Rieckmann. MS-Register in Deutschland: Abschließende Ergebnisse der Pilotphase. Neurol Rehabil 2007; 13 (4): 193 - 200
  • Flachendecker P, Stuke K, Elias W, Freidel M, Haas J, Pischnau-Michel D, Schimrigk S, Zettl U, Rieckmann P. Multiple-Sklerose-Register in Deutschland. Deutsches Ärzteblatt. Jg 105. Heft 7. 113-119

2006

  • Schimrigk S Multiple Sklerose: Immuntherapie im Alltag. Psychoneuro 2006;32(3): 145-148 
  • Schimrigk S, Brune N, Maier D, Rieks M, Hoffman V, Pöhlau D, Przuntek H. Oral fumaric acid esters for treatment of active multiple sclerosis: An open-label, baseline-controlled study.  European Journal of Neurology 2006, 13: 604-610 
  • Hellwig K, Schimrigk S, Lukas C, Hoffmann V, Brune N, Przuntek H, Muller T. Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients. Cln Neuropharmacol. 2006 Sep-Oct;29(5):286-91. 
  • Hellwig K, Brune N, Schimrigk S, Przuntek H, Muller T. Repeated intrathecal triamcinolone acetonide application reduces acute occurring painful dysesthesia in patients with relapsing remitting multiple sclerosis. ScientificWorldJournal. 2006 Apr 6;6:460-5. 
  • Hoffmann V, Kuhn W, Schimrigk S, Islamova S, Hellwig K, Lukas C, Brune N, Pöhlau D, Przuntek H, Müller T. Repeat intrathecal triamconolone acetonide application is beneficial in progressive MS-patients. Eur J Neurol 2006;13(1):72-6. 
  • Zipp F, Hartung HP, Hillert J, Schimrigk S, Trebst C, Stangel M, Infante-Duarte C, Jakobs P, Wolf C, Sandbrink R, Pohl C, Filippi M; CCR1 Antagonist Study Group.  Blockade of chemokine signaling in patients with multiple sclerosis. Neurology 2006 Nov 28;67(10):1880-3. 

2005

  • Schimrigk S, Brune N, Hellwig K, Rieks M, Hoffmann V, Pöhlau D, Przuntek H
    An open-label, prospective study of oral fumaric acid therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS). Neurology. 2005; 64 Suppl.(6): A392-393. 
  • P. Flachenecker, U. K. Zettl, U. Götze, J. Haas, S. Schimrigk, W. Elias, M. Pette, M. Eulitz, M. Hennig, J. Bertram, R. Hollweck, A. Neiss, M. Daumer, D. Pitschnau-Michel, P. Rieckmann. MS-Register in Deutschland - Design und erste Ergebnisse der Pilotphase. Nervenarzt 2005 76:967-975 
  • Zipp F, Hartung HP, Hillert J, Schimrigk S, Trebst C, Stangel M, Pohl C, Filippi M. Blockade of chemokine receptor in multiple sclerosis patients. Mult Scler. 2005; 11: S13 
  • Goedde R, Brune S, Jagiello P, Sindern E, Haupts M, Schimrigk S, Muller N, Epplen JT.An extended association screen in multiple sclerosis using 202 microsatellite markers targeting apoptosis-related genes does not reveal new predisposing factors. J Negat Results Biomed. 2005 Sep 5;4:7. 
  • Goedde R, Rohde K, Becker C, Toliat MR, Entz P, Suk A, Muller N, Sindern E, Haupts M, Schimrigk S, Nurnberg P, Epplen JT.Association of the HLA region with multiple sclerosis as confirmed by a genome screen using >10,000 SNPs on DNA chips. J Mol Med. 2005 Mar 16

2004

  • Schimrigk S, Brune N, Hellwig K, Rieks M, Hoffmann V, Pöhlau D, Przuntek H.
    A prospective, open label, phase II study of oral fumarate therapy for the treatment of relapsing remitting multiple sclerosis. Mult. Skl. 2004; 10 Suppl.(7032): S258-S258. 
  • Fangerau T, Schimrigk S, Haupts M, Kaeder M, Ahle G, Brune N, Klinkenberg K, Kotterba S, Möhring M, Sindern E,  The multiple sclerosis study group. Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria. Acta Neurol Scand 2004: 109: 385-389. 
  • Brune N, Schimrigk S, Meier D, Rieks M, Krane M, Hoffmann V, Pöhlau D, Hellwig K, Przuntek H. Oral fumarate therapy alters cytokine production in patients with relapsing remitting multiple sclerosis. Multiple Sclerosis 2004; 10 Suppl.(7032): S259-S259. 
  • Lukas C, Hahn HK, Bellenberg B, Rexilius J, Schmid G, Schimrigk SK, Przuntek H, Köster O, Peitgen HO.  Sensitivity and reproducibility of a new fast 3D segmentation technique for clinical MR-based brain volumetry in multiple sclerosis. Neuroradiology. 2004;46(11):906-15. 
  • Hellwig K, Brune N, Müller T, Przuntek H, Schimrigk S Efficacy and safety of repeated intrathecal triamconolone acetonide application in acute painful dysaesthesia due to inflammatory spinal cord lesion in patients with relapsing remitting multiple sclerosis. J Neurol 2004; 251 Suppl.: 61-62 
  • Goedde R, Nigmatova V, Jagiello P, Sindern E, Haupts M, Schimrigk S, Epplen JT. Refining the results of a whole-genome screen based on 4666 microsatellite markers for defining predisposition factors for multiple sclerosis. Electrophoresis. 2004 Jul;25(14):2212-8.

2003

  • Hoffmann V, Schimrigk S, Islamova S, Hellwig K, Lukas C, Brune N, Pöhlau D, Przuntek H, Müller T. Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. J of the Neurological Sciences 2003;211:81-84. 
  • Maike Rieks, Volker Hoffmann, Orhan Aktas, Miriam Juschka, Iris Spitzer, Nils Brune, Sebastian Schimrigk, Horst Przuntek, Dieter Pöhlau. Induction of Apoptosis of CD4+ T Cells by Immunomodulatory Therapy of MS with Glatiramer Acetate. Eur Neurol 2003;50:200-206

2002

  • Miterski B, Sindern E, Haupts M, Schimrigk S, Epplen, JT. PTPRC (CD 45) is not asscciated with multiple sclerosis in a large cohort of German patients. BMC Medical Genetics 2002;3:3 
  • Goedde R, Sawcer S, Boehringer S, Miterski B, Sindern E, Haupts M, Schimrigk S, Compston A, Epplen JT. A genome screen for linkage disequilibrium in HLA-DRB1*15-positive Germans with multiple sclerosis based on 4666 microsatellite markers. Hum Genet. 2002 Sep;111(3):270-7. 
  • Miterski B, Böhringer S. Klein W, Sindern E, Haupts M, Schimrigk S, Epplen, JT. Inhibitors in the  NfkappaB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations. Genes Immun. 2002 Jun;3(4):211-9

2001

  • Aktas O, Ari N, Rieks M, Hoffmann V, Schimrigk S, Przuntek H, Poehlau D. Multiple sclerosis: Modulation of apoptosis susceptibility by glatiramer acetate. Acta Neurol Scand. 2001 Nov;104(5):266-70. 
  • Frese, A., Friedrich H., Pöhlau D., Schimrigk S., Bethke F., Husstedt I.W., Evers S.: The prevalence of migraine in multiple sclerosis patients. Cephalalgia 2001; 21: 317.

2000

  • Pöhlau D, Aktas O, Heesen C, Hoffmann V, Schimrigk S, Haupts M. Glatirameracetate (COP-I) zur Behandlung der Multiplen Sklerose. Arzneimitteltherapie (2000) 18; 229-234. 
  • Pöhlau D, Kiltz U, Rieks M, Hoffmann V, Rebmann V, Schimrigk S, Grosse-Wilde H, Przuntek H. Therapeutic immunoadsorbtion increases the level of circulating soluble HLA molecules (2000) . Vox Sang 78: 119-121

1999

  • Schimrigk S, Meier D, Brune N, Krane M, Hellwig K, Hoffmann V, Rieks M, Pöhlau D, Przuntek H. Oral Fumaric Acid Ester (FAE) in Relapsing-Remitting Multiple Sclerosis (RRMS). A Short Term, Open, Clinical, Immunological and Magnetic Resonance Imaging (MRI) Controlled Phase II Trial. J of Neurology (1999) Vol 246 suppl. 1: 36 
  • Schimrigk S, Krane M, Brune N, Hellwig K, Rieks M, Pöhlau D, Przuntek H.
    In Vitro Stimulation Of Peripheral Blood Lymphocytes With Calcium Monomethylfumarate (CaMF) Influence Production Of Intracellular TH1- and TH2-Type Cytokines In A Specific Manner. J Neurol (1999) Vol 246 1: 61

1997

  • Winkel R*, Schimrigk S*, Kuhn W, Amoiridis G, Klotz P, Przuntek H. Gehäuftes Auftreten von Parkinsonsyndromen in einer Gruppe von Postangestellten, die jahrelang mit Blei-Schwefelsäure-Batterien arbeiteten. Nervenheilkunde (1997) 16: 7-8. 
  • Andrich J, Amoiridis G, Schöls L, Schimrigk S, Rieks M, Przuntek H. Autonome Dysregulation bei Amyotrophischer Lateralsklerose (ALS). In Vegetativum-Schlaf-Schmerz von Huffmann G, Braune HJ, Fritz C, Rössy W (Hrsg). Einhorn-Presse Verlag (1997) S. 83-87 
  • Pöhlau D, Nastos I, Postert T, Hoffmann V, Schimrigk S, Przuntek H. Remyelinisierung im Zentralnervensystem als kausales Therapieprinzip? In Vegetativum-Schlaf-Schmerz von Huffmann G, Braune HJ, Fritz C, Rössy W (Hrsg). Einhorn-Presse Verlag (1997) S. 354-361.

1996

  • Schimrigk S, Amoiridis G. Extrapontine myelinolysis. Journal of Neurology, Neurosurgery, and Psychiatrie (1996); 61: 250. 
  • Pöhlau D, Postert T, Hoffmann V, Rieks M, Schimrigk S, Nastos I, Przuntek H. Die Behandlung der Multiplen Sklerose mit Copolymer 1. Nervenheilkunde (1996) 15:110-5.

1995

  • Schimrigk S, Rieks M, Bode A, Schilling P, Alberti T, Hörstgen H, Pöhlau D, Przuntek H
    Quantitive Analysis of intracellular TH1 and TH2 Cytokines an surface markers in patients with multiple sclerosis and control groups. J Neurol 1995 Vol 144: suppl 1: 44

1993

  • Bucka C, Köhler W, Hertel G, Voigt W, Bennhold I, Schimrigk S, Lange R. Immunadsorbtion bei Myasthenia gravis. Wirkungsweise, immunologische Parameter und klinischer Verlauf. Akt. Neurol. (1993)  20: 207-213.

1992

  • Schimrigk S, Lange R, Kölmel HW. Observation of T-Lymphocyte receptors (CD4, CD8, CD25 and HLA-DR) and serum cytokines (IL1 and IL-2) as possible activation and progression markers in multiple sclerosis. Journal of Neurology (1992) 239 (Supp. 2): S. 98